Biohaven, Ltd.Biohaven, Ltd.
  • About
    • Overview
    • Our People
      • Meet Our CEO
    • Board of Directors
    • Scientific Advisory Board
    • Global Collaboration
  • Innovation
    • Pipeline
    • Innovation Engine
    • Clinical Trials at Biohaven
    • Publications
  • Media
    • Top News
    • In The News
    • Media Resources
  • Investors
    • Overview
    • Press Releases
    • Events and Presentations
      • Upcoming and Recent Events
    • Financial Filings
      • SEC Filings
    • Stock Information
      • Stock Quote & Chart
      • Historical Lookup
    • Corporate Governance
      • Governance Documents
      • Committees
    • Contact
  • Commitment
    • Overview
    • Early Access Programs
  • Careers
    • Overview
    • #BeBiohaven
  • Contact
Search
BHVN LISTED NYSE BHVN LISTED NYSE
  • About
    • Overview
    • Our People
      • Meet Our CEO
    • Board of Directors
    • Scientific Advisory Board
    • Global Collaboration
  • Innovation
    • Pipeline
    • Innovation Engine
    • Clinical Trials at Biohaven
    • Publications
  • Media
    • Top News
    • In The News
    • Media Resources
  • Investors
    • Overview
    • Press Releases
    • Events and Presentations
      • Upcoming and Recent Events
    • Financial Filings
      • SEC Filings
    • Stock Information
      • Stock Quote & Chart
      • Historical Lookup
    • Corporate Governance
      • Governance Documents
      • Committees
    • Contact
  • Commitment
    • Overview
    • Early Access Programs
  • Careers
    • Overview
    • #BeBiohaven
  • Contact

Next-Gen ADC

  • Pipeline
  • Innovation Engine
  • Clinical Trials at Biohaven
  • Publications
  • Kv7
  • IgG DEGRADER
  • ADCs
  • NEXT-GEN ADC

ARM™ – NEXT GENERATION BISPECIFIC MOLECULES

Biohaven ARM - bispecific molecules that recruit endogenous antibodies to target cancer

Antibody Recruiting Molecules (ARMs) are bispecific molecules that recruit endogenous antibodies to target cancer, virally infected cells, and disease-causing microorganisms for immune-mediated clearance.

Biohaven ARM - directly engage patients immune system to destry disease cells
Biohaven, Ltd.
  • About
    • Overview
    • Our People
    • Board of Directors
    • Scientific Advisory Board
    • Global Collaboration
  • Media
    • Top News
    • In The News
    • Media Resources
  • Commitment
    • Overview
    • Early Access Programs
  • Innovation
    • Pipeline
    • Innovation Engine
    • Clinical Trials at Biohaven
    • Publications
  • Careers
    • Overview
    • #BeBiohaven
  • Contact
  • About
  • Pipeline
  • Media
  • Investors
  • Commitment
  • Careers
  • Contact
  • Investors
    • Overview
    • Press Releases
    • Events and Presentations
    • Financial Filings
    • Stock Information
    • Corporate Governance
    • Contact

BHVN


LISTED


NYSE

facebook twitter youtube instagram linkedin

BIOHAVEN, LTD.

©2025 Biohaven, Ltd.

  • Terms & Conditions
  • Privacy
  • Social
  • Cookies